Detalhe da pesquisa
1.
Time-series blood cytokine profiles correlate with treatment responses in triple-negative breast cancer patients.
Br J Cancer
; 130(6): 1023-1035, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38238427
2.
Long-term outcomes of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1 + P) and docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP) for HER2-positive primary breast cancer: results of the randomized phase 2 JBCRG20 study (Neo-peaks).
Breast Cancer Res Treat
; 2024 May 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-38767786
3.
Genomic landscape of comprehensive genomic profiling in patients with malignant solid tumors in Japan.
Int J Clin Oncol
; 2024 May 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-38795236
4.
Selection bias due to delayed comprehensive genomic profiling in Japan.
Cancer Sci
; 114(3): 1015-1025, 2023 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-36369895
5.
Potential value of ctDNA monitoring in metastatic HR + /HER2 - breast cancer: longitudinal ctDNA analysis in the phase Ib MONALEESASIA trial.
BMC Med
; 21(1): 306, 2023 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37580773
6.
Efficacy and exploratory biomarker analysis of entinostat plus exemestane in advanced or recurrent breast cancer: phase II randomized controlled trial.
Jpn J Clin Oncol
; 53(1): 4-15, 2023 Jan 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36398439
7.
Evaluation of a novel medical device for pegfilgrastim administration.
Cancer Sci
; 113(5): 1763-1770, 2022 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-35293085
8.
Short- and long-term outcomes of immediate breast reconstruction surgery after neoadjuvant chemotherapy.
Surg Today
; 52(1): 129-136, 2022 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-34089365
9.
Eribulin-based neoadjuvant chemotherapy for triple-negative breast cancer patients stratified by homologous recombination deficiency status: a multicenter randomized phase II clinical trial.
Breast Cancer Res Treat
; 188(1): 117-131, 2021 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-33763789
10.
Surgical upstaging rates in patients meeting the eligibility for active surveillance trials.
Jpn J Clin Oncol
; 51(8): 1219-1224, 2021 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34091677
11.
Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19).
Int J Clin Oncol
; 26(7): 1229-1236, 2021 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-33891194
12.
Ribociclib, a CDK 4/6 inhibitor, plus endocrine therapy in Asian women with advanced breast cancer.
Cancer Sci
; 111(9): 3313-3326, 2020 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-32619077
13.
Long-term survival analysis of addition of carboplatin to neoadjuvant chemotherapy in HER2-negative breast cancer.
Breast Cancer Res Treat
; 180(3): 687-694, 2020 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-32140811
14.
False-negative ultrasound-guided fine-needle aspiration of axillary lymph nodes in breast cancer patients.
Cytopathology
; 31(5): 463-467, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32568448
15.
Predictive factors of an axillary pathological complete response of node-positive breast cancer to neoadjuvant chemotherapy.
Surg Today
; 50(2): 178-184, 2020 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-31367884
16.
[A Case Report on the Effectiveness of Olaparib in a Patient with Recurrent Breast Cancer with Human Immunodeficiency Virus Infection].
Gan To Kagaku Ryoho
; 47(7): 1089-1092, 2020 Jul.
Artigo
em Japonês
| MEDLINE | ID: mdl-32668858
17.
[Toxicity of Palbociclib in Patients Aged 70 Years and Older with Metastatic Breast Cancer].
Gan To Kagaku Ryoho
; 46(7): 1137-1140, 2019 Jul.
Artigo
em Japonês
| MEDLINE | ID: mdl-31296819
18.
SERDs for primary breast cancer.
Lancet Oncol
; 24(9): 947-949, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37657466
19.
Correction to: Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19).
Int J Clin Oncol
; 27(11): 1793, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-36166110
20.
Correction to: Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19).
Int J Clin Oncol
; 26(7): 1237, 2021 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-34043103